Idiopathic Pulmonary Fibrosis Market: High-Growth Opportunities for Investors to 2034 - DelveInsight | GSK, Amgen, Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant

The Key Idiopathic Pulmonary Fibrosis Companies in the market include - Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others .

DelveInsight's report, "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the Idiopathic Pulmonary Fibrosis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Idiopathic Pulmonary Fibrosis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Forecast [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report:

*
The Idiopathic Pulmonary Fibrosis market size was valued at approximately USD 3,300 million in 2023 and is expected to expand at a notable compound annual growth rate (CAGR) throughout the study period from 2020 to 2034.

*
In April 2026, The U.S. The Food and Drug Administration has granted approval for a generic version of Ofev to help reduce lung scarring in patients with idiopathic pulmonary fibrosis. The newly approved generic nintedanib capsules, offered in 100 mg and 150 mg strengths, will be marketed by Cipla. In its announcement, the company noted that the medication will be distributed through standard pharmacy channels, including specialty pharmacy networks.

*
In March 2026, Following a second successful Phase 3 outcome for Tyvaso in idiopathic pulmonary fibrosis, United Therapeutics Corporation is strengthening its case for a potential label expansion and providing greater clarity on its regulatory submission strategy with the U.S. Food and Drug Administration. After what has been described as an "overwhelmingly positive" set of late-stage results, several analysts have echoed the company's optimism that Tyvaso could significantly reshape the treatment landscape for this lung scarring condition, which affects more than 100,000 individuals in the United States.

*
DelveInsight's analysts estimate that the market is expected to show positive growth, mainly attributed to the increase in population and also, and the launch of upcoming therapies during the forecast period (2024-2034).

*
The Idiopathic Pulmonary Fibrosis market size in the EU4 and the UK was nearly USD 702 million and accounted for nearly 21% of the total 7MM market size in 2023.

*
Among the EU4 and the UK, Germany holds the highest market size of around USD 183 million followed by the UK, and France with approximately USD 141 million, and USD 140 million respectively. These numbers are expected to change during the forecast period.

*
The Idiopathic Pulmonary Fibrosis market size in Japan accounted for nearly 5% of the total 7MM market size in 2023, these numbers are expected to rise by 2034.

*
According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM were approximately 193,000 in 2023; this number is expected to increase in the future due to aging populations and improved diagnostic techniques.

*
In 2023, among the 7MM, the US accounted for the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with approximately 95,000 cases. These cases are expected to increase during the forecast period (2024-2034). Among the EU4 and the UK, Germany had the highest diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis with nearly 21,000 cases, followed by the UK, and France with approximately 15,700, and 15,500 diagnosed prevalent cases respectively.

*
In 2023, the prevalence of idiopathic pulmonary fibrosis in the 7MM was distributed as follows: mild (FVC >75%) with 55,926 cases, moderate (FVC 50%-75%) with 96,424 cases, and severe (FVC



This release was published on openPR.